The market for cancer drugs is an ever-roiling mix of shortages of low-cost generics and glut of high-priced brand pharmaceuticals.

This creates challenges for oncologists and oncology practices as they try to develop effective treatment plans for patients based on established drug therapies.

The answer, according to McKesson’s Grant Bogle, senior vice president, pharmaceutical and biotech solutions, is following treatment pathways that prioritize the efficacy, safety and cost of treatment regimens for specific types of cancer.


Be the first to Comment

Start the Conversation

Post a comment:

Please enter a name.

Please enter your comment.

Post Approval in Progress:

System failed to receive comment.

We reserve the right to remove any comments from the site that we feel put the safety or utility of our community at risk. View the . To find out more about our privacy practices, please see the .